Innoviva

Innoviva Liabilities

The The Liabilities of Innoviva (INVA) as of Nov 21, 2026 is 462.32 M USD. In the previous year, The Liabilities was 609.90 M USD — a change of -24.20% (lower).

Liabilities

462.32 MUSD

YoY

-24.20%

Last updated:

In 2025, Innoviva's total liabilities amounted to 462.32 M USD, a -24.20% difference from the 609.90 M USD total liabilities in the previous year.

The Innoviva Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
389.14 M USD
Jan 1, 2019
382.71 M USD
Jan 1, 2020
391.73 M USD
Jan 1, 2021
400.46 M USD
Jan 1, 2022
665.71 M USD
Jan 1, 2023
568.55 M USD
Jan 1, 2024
609.90 M USD
Jan 1, 2025
462.32 M USD
The Innoviva Liabilities history
YEARLiabilitiesYoY
462.32 MUSD-24.20%
609.90 MUSD+7.27%
568.55 MUSD-14.59%
665.71 MUSD+66.24%
400.46 MUSD+2.23%
391.73 MUSD+2.36%
382.71 MUSD-1.65%
389.14 MUSD-36.21%
610.04 MUSD-16.66%
731.99 MUSD-2.61%
751.58 MUSD+0.88%
745.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innoviva Stock analysis

What does Innoviva do? Innoviva Inc - An innovative story Innoviva Inc is a US-based company specializing in the development and marketing of therapy and diagnostic products for respiratory diseases. The company was founded in 1996 under the name Theravance Inc and was renamed Innoviva Inc in 2016. The story of Innoviva Inc began with the goal of developing innovative therapies for chronic respiratory diseases. Over the years, the company expanded and diversified its product portfolio. Today, Innoviva Inc is a leading provider of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Business model of Innoviva Inc The business model of Innoviva Inc is based on the development of products for the treatment of respiratory diseases and collaboration with other pharmaceutical and biotech companies. The company licenses its products to partner companies, which distribute them in the market. This way, Innoviva Inc generates revenue from licensing fees and milestone payments. Divisions of Innoviva Inc Innoviva Inc is divided into three divisions: development, licensing, and financing. The development division is responsible for researching and developing new therapy and diagnostic products. The company works closely with other pharmaceutical and biotech companies in this regard. The licensing division is responsible for licensing products to partner companies. This includes negotiating license agreements and conducting clinical trials. The financing division of Innoviva Inc is responsible for raising external capital. This includes issuing bonds and seeking investment. Products of Innoviva Inc Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. These include: - RELVAR®/BREO® (Fluticasone furoate/Vilanterol) for the treatment of COPD and asthma - ANORO® (Umeclidinium bromide/Vilanterol) for the treatment of COPD - TRELEGY® (Fluticasone furoate/Umeclidinium bromide/Vilanterol) for the treatment of COPD These products have been developed by Innoviva Inc and are licensed to partner companies for distribution. Innoviva Inc is an innovative company specializing in the development and marketing of products for the treatment of respiratory diseases. The business model is based on the development of products and licensing them to partner companies. Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. Innoviva is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Innoviva's Liabilities

Innoviva's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Innoviva's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Innoviva's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Innoviva's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Innoviva’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Innoviva stock

The Liabilities of Innoviva is 462.32 M USD in 2025.

The Liabilities of Innoviva changed from 609.90 M USD to 462.32 M USD, representing a -24.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Innoviva since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Innoviva historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Innoviva

All Key Metrics — Innoviva